CMS expands Medicare drug price negotiations to 15 more medications starting in 2027, including popular diabetes and weight loss treatments, aiming to reduce prescription costs and save Medicare billions.
CMS unveils the GENERous Medicaid payment model introducing MFN drug pricing, alongside expanded Trump administration drug pricing agreements and key regulatory updates for 2026.
FDA approves prescription leucovorin for autism treatment; HHS addresses investment and regulatory concerns involving CMS administrator Dr. Mehmet Oz amid public discourse.
Recent U.S. healthcare updates cover a $34.8M Medicare fraud case, HHS action on organ recovery agency safety, youth fitness legislation, and ACIP's hepatitis B vaccine deliberations.
CMS launches AI-driven pilot to streamline Medicare prior authorization for select services, prompting legislative calls for independent oversight to ensure patient safety and regulatory compliance.
Medicare initiates an AI-based pilot program to aid in approving or denying certain medical procedures, raising considerations about healthcare administrative processes and payer-provider dynamics.
A federal judge blocks major Trump-era ACA provisions that could lead to 1.8 million losing coverage, citing regulatory overreach and increased health costs.
UnitedHealth Group responds to DOJ investigations into Medicare Advantage amid broader insurance market changes including AI automation and pharmaceutical supply dynamics.
CMS's 2026 proposed rules for Medicare Part B include major updates to average sales price calculations, Inflation Reduction Act compliance, ASP documentation, and Medicare inflation rebates affecting government pricing.
Illinois metro-east hospitals brace for Medicaid funding cuts under new federal law, investing in outpatient care to offset losses. Medicaid work requirements and reduced reimbursements alter hospital financial outlook through 2026 and beyond.
